We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amgen eventually agreed to pick up Otezla in a $13.4 billion deal in August, which some analysts called savvy despite concerns the buyout would spark FTC pushback of its own: The drugmaker already markets blockbuster TNF inhibitor Enbrel.